- Home
- HEPS vs ERAS Comparison
HEPS vs ERAS Comparison
Compare HEPS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | ERAS |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.4M | 927.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HEPS | ERAS |
|---|---|---|
| Price | $2.40 | $3.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.07 | ★ $3.71 |
| AVG Volume (30 Days) | 228.0K | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,504,533,586.00 | N/A |
| Revenue This Year | $41.69 | N/A |
| Revenue Next Year | $29.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 56.77 | N/A |
| 52 Week Low | $2.15 | $1.01 |
| 52 Week High | $3.85 | $3.62 |
Technical Indicators
Market Signals| Indicator | HEPS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 65.52 |
| Support Level | $2.32 | $3.15 |
| Resistance Level | $2.46 | $3.48 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 69.05 | 66.16 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.